RGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases.
"In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant...
Started buying in the handle, I feel breakout will happen next week. Price target on pattern 3.61.
Overall price target is 5.00. There is bull flag forming on the handle.
Bullish Flag (47%)
Pros:
Volume during post formation
Descending volume during Flag formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0
R/R ratio above 3
200MA ascending
Cons:
RS flat
ATR flat
250RSI below 50 and flat
Target:
PT = 2.73$
Help how ever you can to keep this alive.
Thank you to those who have donated Coins!
Always do your own due...
RGLS .. We are in full phase two COVID-19. There are many aspects and many pharmaceutical companies that are trying to shine, especially in the research and experimentation of drugs of all kinds ... Let's add that a Master of Biotech finance like Steven Cohen buys 8.5% of shares (5.6 million shares). ..
Remember what happened to COCP when Cohen himself bought...
Pupm&Dump trading strategy idea.
$RGLS is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $0,95;
stop-loss — $1,08;
take-profit — $0,92;
Do not view this idea as a recommendation for trading or...
RGLS: Regulus Therapeutics Inc.
2020-07-29 08:07:00
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326...
Possible break out soon.
Low Risk / Reward to 50 dma
Reason:
Stair stepping on daily making higher lows
Low volume
Indicator: RSI is at 45 and has been increasing (not overbought yet)
MACD still in negative so this might spike soon.
Recent offering in 2018 had created a sell off and currently accumulation has been steadily moving the price higher.
Higher...
Possible pullback play here for a aggressive speculative setup.
* Trade Criteria *
Date First Found- January 10, 2018
Pattern/Why- Long from support; Speculative Pullback play
Entry Target Criteria- Pull back to $1.10; Speculative entry at current price
Exit Target Criteria- Momentum
Stop Loss Criteria- N/A
Special Note- Lots of insider buying
Please check...
$RGLS
50% Fib, Triple Bottom.
This is one of my favorite (combo) patterns to trade. If my statistic is correct, I am about 81% win rate ratio with this combo pattern!
May the odds be with us! G'luck everyone!
RGLS forming a nice fallen angel formation. IT has significant insider buying. It has few moving average to overcome however it has very good upside potential as it is coming down from huge £20 area. To play this we would consider February 2018 $2.50 Calls, currently $0.08
* Trade Criteria *
Date First Found- August 24, 2017 (Intraday Alert)
Pattern/Why-...
